Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Myelodysplastic Syndromes

277 clinical trials

288 products

43 drugs

Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Status: Recruiting, Estimated PCD: 2024-11-15
Product
Placebo
Product
CG-806
Product
Tamibarotene
Product
Azacitidine
Clinical trial
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Terminated, Estimated PCD: 2024-02-13
Product
H3B-8800
Product
REVLIMID®
Clinical trial
Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea
Status: Completed, Estimated PCD: 2023-08-15
Product
Bexmarilimab
Clinical trial
Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Venetoclax
Product
Luspatercept
Clinical trial
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Status: Recruiting, Estimated PCD: 2028-05-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2026-01-01
Product
AK117
Clinical trial
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2026-06-14
Product
SOC + TSC-100
Product
SOC + TSC-101
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-09-21
Product
INCB000928
Clinical trial
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2025-10-06
Product
EP0042
Clinical trial
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-10-01
Product
GLB-001
Product
CC-95251
Clinical trial
An Efficacy and Safety Study of AND017 for the Treatment of Anemia Due to Lower Risk Myelodysplastic Syndromes (MDS)
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-05-16
Product
MBG453
Product
NIS793
Product
canakinumab
Product
Imetelstat
Clinical trial
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
Status: Recruiting, Estimated PCD: 2025-02-01
Product
SL-172154
Product
AND017
Clinical trial
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Status: Terminated, Estimated PCD: 2023-09-13
Product
Magrolimab
Product
MGD024
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-03-01
Product
SOC TSC-101
Product
Oral decitabine/cedazuridine
Product
APG-115
Clinical trial
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2026-05-05
Clinical trial
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Recruiting, Estimated PCD: 2025-04-01
Product
CC-91633
Clinical trial
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML
Status: Recruiting, Estimated PCD: 2026-01-01
Product
TGRX-814
Product
5-azacitidine
Clinical trial
A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-02-28
Product
CFI-400945
Product
LP-108
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LP-108, a BCL-2 Inhibitor, Combined With Azacitidine In Subjects With AML, MDS, CMML
Status: Recruiting, Estimated PCD: 2024-12-31
Product
SGR-2921
Product
Oral decitabine/Cedazuridine
Clinical trial
A Phase Ib Clinical Trial of TQB3454 Tablets in Patients With Blood Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
TQB3454
Product
NKX101
Clinical trial
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Orca-T
Clinical trial
A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Status: Recruiting, Estimated PCD: 2024-07-01
Product
ABD-3001
Clinical trial
First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Allogeneic umbilical cord mesenchymal stem cells
Clinical trial
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2025-06-30
Product
Decitabine
Product
Oral Decitabine + Cedazuridine
Clinical trial
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Myeloid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
PRT1419
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies
Status: Terminated, Estimated PCD: 2024-01-19
Clinical trial
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Product
AG-946
Product
AUR103
Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies( BHARAT-1)
Status: Recruiting, Estimated PCD: 2025-09-16
Product
INKmune
Clinical trial
A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML)
Status: Terminated, Estimated PCD: 2024-03-28
Product
Oral decitabine + Cedazuridine
Product
Lemzoparlimab + Azacitidine
Clinical trial
A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2027-03-31
Product
Durvalumab
Clinical trial
A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Status: Completed, Estimated PCD: 2019-06-19
Product
OrcaGraft
Clinical trial
A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Sabatolimab
Clinical trial
A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Withdrawn, Estimated PCD: 2029-10-26
Clinical trial
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2023-12-15
Product
TJ011133
Product
VOR33
Clinical trial
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Status: Terminated, Estimated PCD: 2019-07-23
Product
rimiducid
Product
Cyclophosphamide
Clinical trial
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Thrombosomes
Product
Liquid Stored Platelets
Product
Mylotarg
Clinical trial
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Status: Active (not recruiting), Estimated PCD: 2023-10-13
Clinical trial
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Status: Active (not recruiting), Estimated PCD: 2026-01-31
Product
KER-050
Clinical trial
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Status: Recruiting, Estimated PCD: 2025-06-30
Product
ASTX727
Clinical trial
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Status: Completed, Estimated PCD: 2021-07-31
Product
Guadecitabine
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents
Status: Completed, Estimated PCD: 2020-03-31
Clinical trial
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Status: Terminated, Estimated PCD: 2021-08-02
Clinical trial
A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Product
rivogenlecleucel
Clinical trial
An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Status: Completed, Estimated PCD: 2018-04-30
Product
DSP-7888
Clinical trial
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2018-08-01
Product
Dacogen
Product
GTB-3550 TriKE
Product
PRGN-3006
Product
Sotatercept
Clinical trial
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome
Status: , Estimated PCD: 2023-12-30
Product
IBI188+azacitidine
Clinical trial
A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF
Status: Terminated, Estimated PCD: 2022-06-10
Product
azacitidine
Clinical trial
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2023-04-05
Product
Jaktinib
Clinical trial
An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Status: Terminated, Estimated PCD: 2023-02-02
Product
venetoclax
Clinical trial
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
Status: Completed, Estimated PCD: 2021-03-19
Product
Docetaxel
Product
DSP107
Clinical trial
A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Status: Completed, Estimated PCD: 2022-01-25
Product
Pevonedistat
Product
MGTA-117
Product
Paclitaxel
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Status: Completed, Estimated PCD: 2022-03-21
Product
Carboplatin
Clinical trial
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Status: Terminated, Estimated PCD: 2022-01-07
Clinical trial
Expanded Access Program: Pevonedistat (in Combination With Azacitidine) for the First-line Treatment of Higher Risk Myelodysplastic Syndromes
Status:
Product
BGB-11417
Clinical trial
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Posaconazole
Clinical trial
A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Status: Completed, Estimated PCD: 2019-01-23
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Status: Terminated, Estimated PCD: 2021-11-05
Product
Talacotuzumab
Product
Daratumumab
Product
Efprezimod
Product
Methotrexate
Product
Tacrolimus
Clinical trial
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia
Status: Completed, Estimated PCD: 2019-09-04
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-67371244 (Bispecific Antibody Targeting CD33 and CD3), in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-03-26
Product
Galinpepimut-S
Clinical trial
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status:
Product
JNJ-67571244
Clinical trial
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-07-23
Clinical trial
A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse/Refractory AML and Relapsed/Progressed High/Very High Risk MDS
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Status: Terminated, Estimated PCD: 2022-12-01
Product
CB-5339
Product
Cytarabine
Clinical trial
A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
RP7214
Product
TQB2928
Product
evorpacept
Clinical trial
An Open-label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 Versus IV Decitabine in Chinese Subjects With Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Decitabine + Cedazuridine
Product
ARGX-110
Product
AZA
Clinical trial
Expanded Access Treatment With Imetelstat For Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Are Transfusion-Dependent And Have Failed to Respond or Have Lost Response or Are Ineligible For Erythropoiesis-Stimulating Agents (ESAs)
Status:
Clinical trial
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-08-01
Product
Alvocidib Plus Decitabine
Clinical trial
A Phase I/Ib, Open-label Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214, a Dihydro-orotate Dehydrogenase (DHODH) Inhibitor, Administered Orally in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Status: Withdrawn, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Status: Terminated, Estimated PCD: 2021-08-16
Clinical trial
Phase Ib Clinical Trial of TQB2928 Injection Combination Therapy in Patients With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-05-01
Product
ONO-7475
Product
ONO-7475 + Venetoclax
Product
Fludarabine
Product
Busulfan
Product
Mesna
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Sirolimus
Product
Mycophenolate Mofetil
Product
Filgrastim
Clinical trial
Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2026-04-01
Product
CTX-712
Product
Rimiducid
Product
Epoetin alfa
Product
Eltrombopag
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Japan Local Phase II Clinical Study Comparing Eltrombopag Monotherapy Versus Placebo in Adult Lower-risk Myelodysplastic Syndromes (MDS) Patients With Platelet Transfusion Dependence
Status: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Phase 2, Multicenter, Single-Arm Bridging Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes(MDS) in Chinese and Japanese Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Status: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Status: Terminated, Estimated PCD: 2020-06-30
Clinical trial
A Phase 2, Multicenter, Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Status: Completed, Estimated PCD: 2022-07-01
Clinical trial
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Status: Completed, Estimated PCD: 2020-12-04
Product
Control
Product
CC-90009
Product
ProTmune
Product
SX-682
Clinical trial
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2011-03-31
Product
Romiplostim
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2023-04-11
Product
NEX-18a
Product
BC3402
Clinical trial
A Phase 1b Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of BC3402 in Combination With Azacitidine in Subjects With Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
Status: Completed, Estimated PCD: 2022-02-10
Clinical trial
Sirolimus+Abatacept+Mycophenolate Mofetil Regimen for Prophylaxis of Acute Graft-versus-host Disease (aGvHD) in Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Who Are Intolerant to Calcineurin Inhibitor
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Product
Abatacept
Drug
mycophenolate mofetil
Product
ATG
Clinical trial
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Status: Active (not recruiting), Estimated PCD: 2009-11-11
Drug
Filgrastim
Drug
cyclophosphamide
Product
Cyclosporine
Drug
Melphalan
Clinical trial
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Status: Active (not recruiting), Estimated PCD: 2024-05-24
Product
Ipilimumab
Product
CD25hi Treg depleted DLI
Clinical trial
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome
Status: , Estimated PCD: 2031-06-01
Clinical trial
A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2027-04-05
Product
KPT-8602
Drug
ASTX727
Clinical trial
Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Status: Not yet recruiting, Estimated PCD: 2029-12-01
Product
Cladribine
Product
Azacitidine or Decitabine
Clinical trial
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2023-02-18
Product
AG-221
Clinical trial
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-12-15
Product
Bortezomib + Clofarabine
Clinical trial
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Recruiting, Estimated PCD: 2025-02-01
Drug
Ivosidenib
Clinical trial
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Status: Recruiting, Estimated PCD: 2024-06-28
Product
Canakinumab
Clinical trial
A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (PRAISE-IR)
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
Thiotepa
Drug
GCSF
Product
Bendamustine
Clinical trial
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Status: Completed, Estimated PCD: 2024-04-30
Clinical trial
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Status: Completed, Estimated PCD: 2023-12-20
Product
T cells (Tcon) and Regulatory T cells (Treg)
Clinical trial
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Vorinostat
Product
G-csf
Product
Blinatumomab
Clinical trial
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Status: Completed, Estimated PCD: 2022-10-06
Product
Vitamin C
Clinical trial
A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Status: Recruiting, Estimated PCD: 2027-05-19
Product
Eprex
Clinical trial
A Clinical Study of Azacitidine Combined With BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome With Moderate High IPSS-M Score
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Drug
CPX-351
Clinical trial
Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2011-03-01
Product
CD3-depleted/CD56+ selected natural killer cells
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Status: Active (not recruiting), Estimated PCD: 2024-09-17
Clinical trial
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Status: Completed, Estimated PCD: 2020-09-15
Product
CC-486
Clinical trial
Pilot Study of Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
Status: Recruiting, Estimated PCD: 2027-05-31
Drug
Atorvastatin
Product
Rosuvastatin
Clinical trial
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-06-17
Product
Itacitinib
Clinical trial
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
Status: , Estimated PCD: 2024-08-01
Product
Interferon gamma-primed human bone marrow-derived mesenchymal stromal cells
Clinical trial
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Status: Recruiting, Estimated PCD: 2027-09-20
Drug
decitabine
Product
spartalizumab
Product
sabatolimab
Clinical trial
A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS
Status: Terminated, Estimated PCD: 2009-10-13
Product
filgrastim
Product
clofarabine
Drug
cytarabine
Product
Microarray Analysis
Clinical trial
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-02-01
Drug
fludarabine
Clinical trial
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
Status: Recruiting, Estimated PCD: 2027-12-31
Product
NTX-301
Clinical trial
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Status: Active (not recruiting), Estimated PCD: 2024-08-10
Product
CD8 Depleted
Product
Standard of Care Chemotherapy
Clinical trial
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)
Status: Completed, Estimated PCD: 2017-03-03
Product
Dasatinib
Clinical trial
A Multicenter, Single-arm, Open-label Phase II Study of the Safety of Lenalidomide Monotherapy and Markers for Disease Progression in Patients With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Associated With an Isolated Deletion 5q Cytogenetic Abnormality (Del 5q)
Status: Completed, Estimated PCD: 2018-05-24
Product
Lenalidomide
Clinical trial
IDH2-Post-Allo-Trial: Enasidenib as Consolidation or Salvage Therapy for Patients With IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
Enasidenib
Clinical trial
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2024-05-16
Product
Omacetaxine
Clinical trial
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Status: Withdrawn, Estimated PCD: 2027-04-01
Product
Fludarabine + Total Marrow Irradiation
Clinical trial
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2021-11-27
Clinical trial
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDS
Status: Recruiting, Estimated PCD: 2025-10-31
Product
Treg-enriched donor cell
Product
Unmodified donor T Cell
Clinical trial
Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Status: Withdrawn, Estimated PCD: 2025-12-01
Drug
Sitagliptin
Product
Bortezomib
Clinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation
Status: Completed, Estimated PCD: 2008-12-30
Product
Pentostatin
Product
Cyclosporine A
Clinical trial
Allogeneic Hematopoietic Cell Transplantation With Cyclophosphamide, Fludarabine, and Antithymocyte Globulin in Lower Risk Myelodysplastic Syndrome Phase 2 Extension Study
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Product
Cyclophosphamide + Fludarabine + Antithymocyte Globulin
Clinical trial
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Mycophenylate mofetil
Product
Umbilical cord blood
Clinical trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-04-02
Clinical trial
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2025-12-01
Product
cyclosporine
Product
melphalan
Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2025-02-07
Clinical trial
Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies
Status: Terminated, Estimated PCD: 2011-05-17
Drug
busulfan
Drug
etoposide
Clinical trial
Efficacy and Safety of Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide for Graft-versus-host Disease Prophylaxis in Higher-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, and Secondary AML Patients
Status: Active (not recruiting), Estimated PCD: 2027-05-31
Clinical trial
A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
Status: Recruiting, Estimated PCD: 2025-10-01
Drug
Danvatirsen
Product
Danvatirsen + Venetoclax
Clinical trial
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
Status: Recruiting, Estimated PCD: 2027-06-25
Product
Epoetin Alfa
Clinical trial
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders
Status: Active (not recruiting), Estimated PCD: 2007-03-13
Product
Fludarabine phosphate
Drug
methotrexate
Drug
sirolimus
Clinical trial
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Very Low-dose Total Body Irradiation in Combination With Total Lymphoid Irradiation and Anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-Myeloablative Hematopoietic Cell Transplantation
Status: Completed, Estimated PCD: 2019-12-26
Product
Anti-thymocyte globulin
Product
Mycophenolate mofetil
Clinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Status: Completed, Estimated PCD: 2024-02-02
Product
Tetanus-CMV Fusion Peptide Vaccine
Clinical trial
Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase II, Open-label, Single Arm Study to Evaluate the Efficacy of Luspatercept in Erythropoiesis-stimulating Agent Naive Lower-risk MDS Patients With or Without Ring Sideroblasts Who do Not Require RBC Transfusions
Status: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2025-01-10
Product
HSCT with TBI Regimen
Product
HSCT
Clinical trial
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Status: Recruiting, Estimated PCD: 2026-06-02
Drug
tacrolimus
Clinical trial
Prospective Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - the EUROPE-trial
Status: Completed, Estimated PCD: 2021-07-01
Product
N-Plate
Clinical trial
Graft-Versus-Tumor Augmentation With Nivolumab for High-Risk Patients With MDS and AML After Allogeneic Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide
Status: Withdrawn, Estimated PCD: 2021-04-20
Drug
T-VEC
Clinical trial
A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Chimeric antigen receptor T cells
Product
Peptide Specific Dendritic Cell
Clinical trial
A Phase 1, FIH, Dose Escalation Study of JNJ-74856665 (Dihydroorotate Dehydrogenase [DHODH] Inhibitor) Alone or in Combination in Participants With AML or MDS
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
JNJ-74856665
Clinical trial
A Prospective, Single-arm Clinical Study to Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FLU-BU-MEL Conditioning for Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Fludarabine, Busulfan and Melphalan
Clinical trial
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment
Status: Recruiting, Estimated PCD: 2024-12-01
Product
VEN
Product
Darbepoetin Alfa
Clinical trial
A Phase 1/2 Multicenter Open-label Study to Investigate Treatment of Hydroxyurea in Combination With Valproic Acid (VPA), or 6- Mercaptopurine in Combination With VPA in Patients With AML or HR-MDS Unfit for Standard Therapy
Status: Not yet recruiting, Estimated PCD: 2025-11-30
Product
Hydroxyurea
Product
Valproic acid
Product
6-Mercaptopurine
Clinical trial
Phase-I/II Trial to Assess the Safety and Efficacy of Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (FLAMSAClax
Status: Recruiting, Estimated PCD: 2026-01-31
Product
Amsacrine
Product
Ara-C
Clinical trial
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
ASTX029
Product
TCRα/β+
Product
CD19+
Product
CD45RA-depleted DLI
Clinical trial
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Status: Terminated, Estimated PCD: 2023-02-02
Product
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
Product
BMS-986253
Clinical trial
Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups
Status: Completed, Estimated PCD: 2019-04-04
Product
Caspofungin
Clinical trial
A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients With High-Risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-09-06
Clinical trial
Haploidentical Stem Cell Transplantation With or Without NK Cell Infusion in Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome:The BigEMINy Study
Status: Terminated, Estimated PCD: 2023-09-28
Product
Haplo SCT
Clinical trial
Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.
Status: Withdrawn, Estimated PCD: 2017-01-01
Product
Deferasirox
Clinical trial
A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS
Status: Completed, Estimated PCD: 2022-09-06
Product
Ruxolitinib
Product
Donor Lymphocyte Infusion
Drug
azacitidine
Drug
venetoclax
Product
INQOVI
Clinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Vactosertib
Product
Post-Transplant Cyclophosphamide
Clinical trial
A Phase II Multicenter Single-armed Study Using Subject-specific Minimal Residual Disease Markers to Adopt Treatment After Allogeneic Stem Cell Transplantation for Subjects With Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Status: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2020-10-09
Product
Pembrolizumab
Clinical trial
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2028-04-19
Clinical trial
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia
Status: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2017-08-10
Clinical trial
A Pilot Study of ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After an Allogeneic Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Drug
ONC201
Clinical trial
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
Status: Recruiting, Estimated PCD: 2023-08-24
Drug
Defactinib
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-02-01
Product
Umbilical Cord Blood
Product
Decetabine
Clinical trial
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Status: Recruiting, Estimated PCD: 2029-08-01
Clinical trial
Multiple-center Randomized Study to Compare Fludarabine and Busulfan Versus Fludarabine, Busulfan and Melphalan in Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplasia Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Fludarabine + Busulfan + Melphalan
Product
Fludarabine + Busulfan
Clinical trial
A Pilot Study of IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2023-10-30
Product
IFN-γ
Drug
Tocilizumab
Clinical trial
A Phase II Trial of Venetoclax-Enhanced Reduced Intensity HLA-Mismatched Allogeneic Transplant for Ultra-High-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status: Not yet recruiting, Estimated PCD: 2026-08-31
Clinical trial
Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2013-08-01
Clinical trial
Interferon-α for Preventing Relapse in TP53+ Myeloid Malignancy Post Allo-HSCT
Status: Recruiting, Estimated PCD: 2024-12-31
Product
IFN-Α
Product
Hydrocortisone
Drug
mFOLFOX6
Product
Dexamethasone
Drug
Vincristine
Product
Doxorubicin
Product
Dexrazoxane
Product
Calaspargase Pegol
Drug
Erwinia asparaginase
Clinical trial
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Status: Recruiting, Estimated PCD: 2033-06-01
Product
Genomic profiling
Clinical trial
An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia
Status: , Estimated PCD: 2025-02-01
Clinical trial
Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial
Status: Not yet recruiting, Estimated PCD: 2028-02-01
Product
Hematopoietic stem-cell transplantation
Clinical trial
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Status: Completed, Estimated PCD: 2019-06-07
Product
Rabbit ATG
Clinical trial
Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide in Myelodysplastic Syndrome Patients
Status: Completed, Estimated PCD: 2021-12-16
Clinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant
Status: Not yet recruiting, Estimated PCD: 2025-10-29
Product
ATG Combined with Tacrolimus and Mini Methotrexate
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2010-04-12
Drug
etoposide
Clinical trial
Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to ESA
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Sodium Valproate
Product
Danazol
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2027-10-22
Product
Peripheral Blood Stem Cell Transplant
Clinical trial
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
Matched placebo
Clinical trial
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status: Active (not recruiting), Estimated PCD: 2020-06-23
Product
Granulocyte Colony-Stimulating Factor
Clinical trial
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Status: Not yet recruiting, Estimated PCD: 2030-01-01
Product
pacritinib
Clinical trial
Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory Myelodysplastic Syndrome With Ring Sideroblasts (MDS-RS): A Prospective Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Product
Roxadustat
Clinical trial
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine
Status: Active (not recruiting), Estimated PCD: 2025-08-25
Clinical trial
MT2017-17:T Cell Receptor Alpha/Beta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Total Body Irradiation (TBI)
Product
Methylprednisolone
Clinical trial
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-04-24
Drug
Varlilumab
Clinical trial
Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin
Status: Completed, Estimated PCD: 2008-02-01
Product
Anti-Thymocyte Globulin
Clinical trial
A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Darzalex Faspro
Clinical trial
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-11
Clinical trial
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Status: Recruiting, Estimated PCD: 2033-11-30
Product
DEC-C
Clinical trial
Contribution of Anti-platelet Antibodies Identified With" Monoclonal Antibody Immobilization of Platelet Antigens" Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Status: Recruiting, Estimated PCD: 2027-05-01
Product
Blood samples
Clinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2028-12-01
Product
Daunorubicin
Clinical trial
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Terminated, Estimated PCD: 2012-12-19
Drug
rituximab
Product
Graft Versus Host Disease Prophylaxis/Therapy
Product
Graft-Versus-Tumor Induction Therapy
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Status: Completed, Estimated PCD: 2023-04-17
Clinical trial
Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment
Status: Completed, Estimated PCD: 2023-07-15
Clinical trial
Efficacy Evaluation of Post-transplant Cyclophosphamide-based Graft-versus-host Disease Prophylaxis With ATG, Calcineurin Inhibitor-free, for Matched-sibling or Matched-unrelated Transplantation
Status: Not yet recruiting, Estimated PCD: 2031-06-01
Product
ATG 5.0
Clinical trial
Phase III Evaluation of EPO With or Without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2008-08-01
Product
Erythropoietin
Clinical trial
A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation
Status: Completed, Estimated PCD: 2011-01-01
Product
Gene Expression Analysis
Product
Reverse Transcriptase-Polymerase Chain Reaction
Clinical trial
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS
Status: Recruiting, Estimated PCD: 2024-02-05
Drug
IMM01
Clinical trial
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
Status: Not yet recruiting, Estimated PCD: 2029-10-01
Product
CD34 selected hematopoietic stem cells
Clinical trial
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-08-21
Product
CD45RA-depleted peripheral blood mononuclear cells
Clinical trial
Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors
Status: Completed, Estimated PCD: 2011-08-01
Product
Alentuzumab
Product
Globulina antilinfocitaria
Clinical trial
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)
Status: Completed, Estimated PCD: 2020-10-05
Drug
Docetaxel
Clinical trial
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2014-02-01
Product
Photopheresis
Product
Mycofenolate mofetil
Clinical trial
K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome
Status: Terminated, Estimated PCD: 2009-10-01
Product
K562/GM-CSF cell vaccine
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-09-01
Drug
FHD-286
Product
Low Dose Cytarabine
Clinical trial
A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Status: Terminated, Estimated PCD: 2023-08-21
Product
Decitabine/Cedazuridine
Clinical trial
An Open-Label, Multicenter, Extension Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
Status: , Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Biological Sampling
Clinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Recruiting, Estimated PCD: 2028-05-22
Product
Conditioning Chemotherapy
Product
Cord blood graft
Clinical trial
Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical Trial
Status: Recruiting, Estimated PCD: 2026-02-28
Product
Cytokine Induced Memory-like Natural Killer Cells
Clinical trial
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)
Status: Terminated, Estimated PCD: 2008-04-01
Product
KW-2449
Clinical trial
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Status: Terminated, Estimated PCD: 2021-06-30
Product
IGF/MTX
Clinical trial
Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2019-12-31
Product
Treosulfan
Clinical trial
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
Status: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor
Status: Recruiting, Estimated PCD: 2026-12-01
Drug
JAKi
Clinical trial
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Status: Recruiting, Estimated PCD: 2027-11-30
Product
Allopurinol
Clinical trial
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Calcineurin Inhibitor at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Product
GVHD prevention
Clinical trial
A Multi-center Prospective Single Arm Clinical Study of Reduced Intensive 3 + 5 Idarubicin and Cytarabine Chemotherapy Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome
Status: Not yet recruiting, Estimated PCD: 2026-04-02
Drug
idarubicin
Clinical trial
A Multi-center Prospective Single Arm Clinical Study of Prolonged Ultra Low-dose Decitabine Combined With Venetoclax (Bcl-2 Inhibitor) as First Line Treatment for Elderly Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2025-10-19
Product
VENCLYXTO
Product
CD8+ Memory T Cell Infusion
Product
Levetiracetam
Product
Bone Marrow Cell Transplant
Clinical trial
Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome
Status: Withdrawn, Estimated PCD: 2018-03-31
Drug
Arsenic Trioxide
Clinical trial
Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2023-01-05
Product
tretinoin
Product
DNA methylation analysis
Product
Cytogenetic Analysis
Clinical trial
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Status: Terminated, Estimated PCD: 2024-02-29
Clinical trial
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes With del5q, Refractory/Resistant/Intolerant to Prior Treatments, Who Require Red Blood Cell Transfusions
Status: Recruiting, Estimated PCD: 2024-04-03
Product
MGTA 456
Clinical trial
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Status: , Estimated PCD: 2024-12-01
Product
CIML NK
Clinical trial
A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Navitoclax
Clinical trial
A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
Status: Recruiting, Estimated PCD: 2025-05-01
Drug
alemtuzumab
Clinical trial
A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
Status: Completed, Estimated PCD: 2022-11-06
Product
Polymerase Chain Reaction
Product
Polymorphism Analysis
Product
Thymoglobulin
Clinical trial
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS .
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
BST-236
Drug
Allopurinol
Product
Immunosuppressive therapy
Product
Peripheral Blood Stem Cells
Product
Bone Marrow Cells
Clinical trial
A Prospective Single-center Study on the Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Drug
lenalidomide
Clinical trial
A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS
Status: Completed, Estimated PCD: 2010-03-18
Clinical trial
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Status: Recruiting, Estimated PCD: 2025-03-31
Product
VIC- 1911
Clinical trial
A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts
Status: , Estimated PCD: 2009-06-01
Drug
GM-CSF
Product
Zosuquidar
Clinical trial
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Status: Recruiting, Estimated PCD: 2026-03-15
Product
REM-422
Clinical trial
A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
Status: Terminated, Estimated PCD: 2024-03-06
Product
CA-4948
Clinical trial
Umbilical Cord Blood Transplantation From Unrelated Donors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
Status: Recruiting, Estimated PCD: 2024-10-13
Product
Anti-Thymocyte globulin
Clinical trial
Evaluation of the Diagnostic/Therapeutic Course of Patients With Autoimmune Cytopenias (Autoimmune Hemolytic Anemia AIHA, Immune Thrombocytopenia ITP, Chronic Idiopathic/Autoimmune Neutropenia CIN/AIN) and Identification of Predictive and Prognostic Markers.
Status: Recruiting, Estimated PCD: 2026-09-01
Product
Cytokine Essays
Product
NGS
Product
Fecal microbiome
Product
Thrombopoietin Receptor Agonist
Clinical trial
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06.
Status: Withdrawn, Estimated PCD: 2004-04-07
Product
Amifostine
Product
Mitoxantrone
Clinical trial
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Status: Recruiting, Estimated PCD: 2026-08-31
Product
CAR.70/IL15-transduced CB-NK cells
Clinical trial
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Status: Recruiting, Estimated PCD: 2025-12-11
Product
SAR443579
Clinical trial
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2024-01-01
Product
EAGD T-cell infusion
Clinical trial
A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2016-12-05
Product
vosaroxin
Clinical trial
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Status: Recruiting, Estimated PCD: 2031-03-31
Clinical trial
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ASTX030
Product
Cedazuridine
Clinical trial
A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem/Progenitor Transplantation
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Hyperbaric oxygen
Drug
interleukin-2
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Status: Active (not recruiting), Estimated PCD: 2022-04-26
Product
Hypomethylating agents
Product
Total Body Irradiation
Clinical trial
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Status: Recruiting, Estimated PCD: 2026-04-15
Product
TRX103
Clinical trial
An Open-label, Multicenter, Phase 1 Study to Evaluate Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
TCB008
Clinical trial
A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-09-23
Product
Bemcentinib
Clinical trial
Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
Status: Not yet recruiting, Estimated PCD: 2029-09-01
Product
Venetoclax Plus Azacytidine Conditioning Regimen
Clinical trial
Randomized Trial of Benadamustine Versus Ruxolitinib With Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2028-06-01